Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $195.1 million.

  • Integra Lifesciences Holdings' Cost of Revenue rose 801.51% to $195.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $783.1 million, marking a year-over-year increase of 1101.46%. This contributed to the annual value of $728.5 million for FY2024, which is 1090.5% up from last year.
  • Latest data reveals that Integra Lifesciences Holdings reported Cost of Revenue of $195.1 million as of Q3 2025, which was up 801.51% from $206.3 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Cost of Revenue peaked at $206.3 million during Q2 2025, and registered a low of $142.6 million during Q1 2022.
  • Its 5-year average for Cost of Revenue is $166.3 million, with a median of $162.0 million in 2024.
  • As far as peak fluctuations go, Integra Lifesciences Holdings' Cost of Revenue soared by 4341.09% in 2021, and later crashed by 532.03% in 2022.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Cost of Revenue stood at $156.2 million in 2021, then decreased by 5.32% to $147.9 million in 2022, then increased by 15.28% to $170.5 million in 2023, then grew by 13.5% to $193.6 million in 2024, then increased by 0.77% to $195.1 million in 2025.
  • Its Cost of Revenue was $195.1 million in Q3 2025, compared to $206.3 million in Q2 2025 and $188.2 million in Q1 2025.